Argee.recent developments(inside),while others just flip in and out i grabbed some more and waiting for updates.:
3 New Patents announced already in June by RXI. Building up extensive collection of IP to go with pipeline.
This stock has been uptrending past few weeks(Especially,past days),shares of RXII have been consistently making higher lows and higher highs, which is bullish technical price action.
Tue, 09 Jun 2015 11:02:00 GMT ~ RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform
[PR Newswire] - MARLBOROUGH, Mass., June 9, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, today announced that it received two Notices of Allowance from the United States Patent and Trademark Office (USPTO). One is on RXi's novel, self-delivering RNAi platform (sd-rxRNA®). The patent, titled "Reduced Size Self-Delivering RNAi Compounds," covers both the composition and methods of use of RXi's self-delivering platform. The patent, once issued, will be scheduled to expire in 2031.
Mon, 08 Jun 2015 11:20:00 GMT ~ The Rising Tide in Larger Markets Spurs New Interest In Small-Cap Stocks
[Accesswire] - CORAL GABLES, FL / ACCESSWIRE / June 8, 2015 / Oil analysts are starting to lean toward a more favorable outcome for oil prices in relation to a prosperous global economy. With that, markets have continued ...
Wed, 03 Jun 2015 11:02:00 GMT ~ RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye
[PR Newswire] - MARLBOROUGH, Mass., June 3, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on its novel, self-delivering RNAi platform (sd-rxRNA®). The patent, titled "RNA Interference in Ocular Indications," covers methods of use of RXi's VEGF-targeting and CTGF-targeting self-delivering rxRNAs®, including RXI-109, for use in the eye. The patent, once issued, will be scheduled to expire in 2031. This core patent, within RXi's intellectual property portfolio, broadens the coverage of RXi's self-delivering platform and provides coverage of RXI-109 for the treatment of ocular fibrosis.